《2022 JSC/JSTDM临床实践指南:替考拉宁治疗药物监测》解读

doi:10.3969/j.issn.1000-8535.2023.02.004

广州医药 ›› 2023, Vol. 54 ›› Issue (2): 24-28.DOI: 10.3969/j.issn.1000-8535.2023.02.004

《2022 JSC/JSTDM临床实践指南:替考拉宁治疗药物监测》解读

王润

红河哈尼族彝族自治州中医医院(红河 654399)

收稿日期:2022-02-19 出版日期:2023-02-20 发布日期:2023-02-27

Interpretation of Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

WANG Run

Honghe Hani and Yi Autonomous Prefecture Hospital of Traditional Chinese Medicine, Honghe 654399, China

Received:2022-02-19 Online:2023-02-20 Published:2023-02-27

摘要/Abstract

摘要： 目的为临床合理使用替考拉宁以及更好地管理接受替考拉宁治疗的患者。方法从药学角度对2022年日本《2022 JSC/JSTDM临床实践指南:替考拉宁治疗药物监测》(简称《指南》)涉及替考拉宁治疗的9个临床问题进行解读。结果《指南》指出药-时曲线下面积/最小抑菌浓度是替考拉宁的关键药动学/药效学参数。替考拉宁治疗药物监测(TDM)的目的是明确目标谷浓度(C_min),对于严重或复杂的耐甲氧西林金黄色葡萄球菌(MRSA)感染,指南建议替考拉宁C_min为20~40 mg/L。肾功能正常或轻度受损的非复杂性的MRSA感染,目标C_min为15~30 mg/L。严重和/或复杂性MRSA感染,如感染性心内膜炎和骨髓炎,替考拉宁C_min为20~40 mg/L。结论《指南》针对不同病理状态下患者替考拉宁目标C_min的确定,为临床治疗中替考拉宁TDM、个体化给药提供参考。

关键词: 替考拉宁, 治疗药物监测, 耐甲氧西林金黄色葡萄球菌, 指南解读, 目标谷浓度

Abstract: Objective To make rational use of teicoplanin and better management of patients treated with teicoplanin. Methods Nine clinical issues related to the treatment of teicoplanin in Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring (Japan, 2022) were interpreted from the perspective of pharmacy. Results The guidelines indicated that the area under drug-time curve/minimum inhibitory concentration was the key pharmacokinetic/pharmacodynamic parameters of teicoplanin.The purpose of therapeutic drug monitoring (TDM) of teicoplanin is to specify the target trough concentration (C_min), which guidelines recommend for severe or complex methicillin-resistant Staphylococcus aureus (MRSA) infection is 20-40 mg/L.The target C_min for uncomplicated MRSA infection with normal or mildly impaired renal function is 15-30 mg/L.For severe and/or complex MRSA infections, such as infective endocarditis and osteomyelitis, the C_minof teicoplanin was 20-40 mg/L. Conclusions The guidelines are aimed at the determination of target C_min of teicoplanin in patients with different pathological conditions, and provide reference for individual drug administration and teicoplanin TDM in clinical treatment.

Key words: teicoplanin, TDM, MRSA, guide interpretation, C_min

王润. 《2022 JSC/JSTDM临床实践指南:替考拉宁治疗药物监测》解读[J]. 广州医药, 2023, 54(2): 24-28.

WANG Run. Interpretation of Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring[J]. Guangzhou Medical Journal, 2023, 54(2): 24-28.

参考文献

[1] UEDA T, TAKESUE Y, NAKAJIMA K, et al.Clinical efficacy and safety inpatients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days[J].BMC Pharmacol Toxicol,2020, 21(1): 50.
[2] HANAI Y, TAKAHASHI Y, NIWA T,et al.Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus infection: a systematic review and meta-analysis[J].J Clin Pharm Ther,2021,46(3): 622-632.
[3] WATANABE E, MATSUMOTO K, IKAWA K,et al.Pharmacokinetic/pharmacodynamic evaluation of teicoplanin against Staphylococcus aureus in amurine thigh infection model[J].J Glob Antimicrob Resist,2021(24): 83-87.
[4] MATSUMOTO K, WATANABE E, KANAZAWA N, et al.Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections[J].Clin Pharmacol,2016(8): 15-18.
[5] RAMOS-MARTÍN V, JOHNSON A, MCENTEE L,et al.Pharmacodynamics of teicoplanin against MRSA[J].J Antimicrob Chemother,2017, 72(12): 3382-3389.
[6] WICHA S G, MÄRTSON A-G, NIELSEN E I,et al.From therapeutic drug monitoring to model-informed precision dosing for antibiotics[J].Clin Pharmacol Ther,2021,109(4): 928-941.
[7] HEINE R T, KEIZER R J, van STEEG K,et al.Prospective validation of amodel-informed precision dosing tool for vancomycin in intensive carepatients[J].Br J Clin Pharmacol,2020,86(12): 2497-2506.
[8] ODA K, HASHIGUCHI Y, KIMURA T,et al.Performance of area under theconcentration-time curve estimations of vancomycin with limited sampling by a newly developed web application[J].Pharm Res,2021, 38(4):637-646.
[9] TSUTSUURA M, MORIYAMA H, KOJIMA N,et al.The monitoring of vancomycin: a systematic review and meta-analyses of area under theconcentration-time curve-guided dosing and trough-guided dosing[J].BMC Infect Dis,2021, 21(1):153.
[10] KONTOU A, SARAFIDIS K, BEGOU O,et al.Population pharmacokinetics of teicoplanin in preterm and term neonates: is it time for a new dosing regimen?[J].Antimicrob Agents Chemother,2020, 64(4): e01971-19.
[11] LI H, GAO L, ZHOU L,et al.Optimal teicoplanin loading regimen to rapidly achieve target trough plasma concentration in critically ill patients[J].Basic Clin Pharmacol Toxicol,2020,126(3): 277-288.
[12] KIM S-H, KANG C-I, HUH K,et al.Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy[J].Eur J Clin Microbiol Infect Dis,2019,38(11): 2113-2120.
[13] BYRNE C J, ROBERTS J A, MCWHINNEY B,et al.Variability in trough totaland unbound teicoplanin concentrations and achievement oftherapeutic drug monitoring targets in adult patients with hematological malignancy[J].Antimicrob Agents Chemother,2017,61(6): e02466-16.
[14] YOSHIDA T, YOSHIDA S, OKADA H,et al.Risk factors for decreased teicoplanin trough concentrations during initial dosing in critically ill patients[J].Pharmazie,2019,74(2): 120-124.
[15] LIM S K, LEE S A, KIM C-W,et al.High variability of teicoplanin concentration in patients with continuous venovenous hemodiafiltration[J].Hemodial Int,2019,23(1): 69-76.

《2022 JSC/JSTDM临床实践指南:替考拉宁治疗药物监测》解读

Interpretation of Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价

[1]	钟璐莲, 陈政, 彭陈陈, 王娟, 盛小茜, 曾环思, 李裕基. 阿立哌唑血药浓度/剂量比影响因素分析及临床应用[J]. 广州医药, 2022, 53(3): 100-103.
[2]	林颜玉, 陈文伟, 王柏旺, 卢玉平. 中山市部分地区金黄色葡萄球菌感染的临床分布及耐药基因研究[J]. 广州医药, 2016, 47(2): 7-9.